Cocrystal Ev To Sales from 2010 to 2025

COCP Stock  USD 1.58  0.02  1.28%   
Cocrystal Pharma EV To Sales yearly trend continues to be relatively stable with very little volatility. EV To Sales is likely to drop to 368.80. EV To Sales is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. View All Fundamentals
 
EV To Sales  
First Reported
2010-12-31
Previous Quarter
388.21
Current Value
368.8
Quarterly Volatility
2.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Interest Expense of 1.7 K, Selling General Administrative of 4.1 M or Selling And Marketing Expenses of 8.9 M, as well as many indicators such as Price To Sales Ratio of 383, Dividend Yield of 0.0 or PTB Ratio of 0.69. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
  
Check out the analysis of Cocrystal Pharma Correlation against competitors.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Latest Cocrystal Pharma's Ev To Sales Growth Pattern

Below is the plot of the Ev To Sales of Cocrystal Pharma over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Cocrystal Pharma's EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cocrystal Pharma's overall financial position and show how it may be relating to other accounts over time.
Ev To Sales10 Years Trend
Slightly volatile
   Ev To Sales   
12.35.3K7.1K28.1431.388.368.42928%34%-100%1434%-10%-5%100%
       Timeline  

Cocrystal Ev To Sales Regression Statistics

Arithmetic Mean1,266
Geometric Mean177.56
Coefficient Of Variation183.70
Mean Deviation1,729
Median388.21
Standard Deviation2,326
Sample Variance5.4M
Range7.1K
R-Value(0.29)
Mean Square Error5.3M
R-Squared0.08
Significance0.28
Slope(141.00)
Total Sum of Squares81.2M

Cocrystal Ev To Sales History

2025 368.8
2024 388.21
2020 431.34
2016 28.12
2015 7080.43
2013 5275.21
2012 12.26

About Cocrystal Pharma Financial Statements

Cocrystal Pharma shareholders use historical fundamental indicators, such as Ev To Sales, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EV To Sales 388.21  368.80 

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…